Acute graft versus host disease (aGvHD)
3
0
0
0
Key Insights
Highlights
Treatment Research
2 treatments under study, led by Apraglutide
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
33.3%
1 terminated out of 3 trials
0%
0 trials in Phase 3/4
0%
1 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Clinical Trials (3)
Proof-of-concept Trial of Apraglutide in Acute Graft Versus Host Disease (aGVHD)
Phase 2 Open Label Prospective Dose-Ranging Clinical Trial with Escalation and Expansion Cohorts to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Dosing, and Efficacy of RLS-0071 for the Treatment of Hospitalized Patients with Steroid -Refractory Acute Graft-versus-Host Disease
Phase 2 Open Label Prospective Dose-Ranging Clinical Trial with Escalation and Expansion Cohorts to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Dosing, and Efficacy of RLS-0071 for the Treatment of Hospitalized Patients with Steroid -Refractory Acute Graft-versus-Host Disease
Research Network
Common Treatments
- Apraglutide1
- Ialilepiccqeraa Peptide Sequence With A Monodisperse Polyethylene Glycol Tail1
Active Sponsors
- ReAlta Life Sciences, Inc.2
- VectivBio AG1
Top Investigators
VectivBio AG
Related Conditions
- Gvhd1